Matches in Wikidata for { <http://www.wikidata.org/entity/Q65345518> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q65345518 description "clinical trial" @default.
- Q65345518 description "ensayu clínicu" @default.
- Q65345518 description "klinisch onderzoek" @default.
- Q65345518 description "клінічне випробування" @default.
- Q65345518 name "Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer" @default.
- Q65345518 name "Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer" @default.
- Q65345518 type Item @default.
- Q65345518 label "Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer" @default.
- Q65345518 label "Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer" @default.
- Q65345518 prefLabel "Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer" @default.
- Q65345518 prefLabel "Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer" @default.
- Q65345518 P1132 Q65345518-00DC6DD5-2F57-42F1-A6CE-464ED9C0D651 @default.
- Q65345518 P1476 Q65345518-7CC6617A-9070-4C34-9EB8-53360C22F089 @default.
- Q65345518 P17 Q65345518-1AEE46B1-2915-4DD6-8E73-70240A13B1E8 @default.
- Q65345518 P17 Q65345518-5F80B3B0-33DF-48A4-A4A9-A692FCAC28B8 @default.
- Q65345518 P17 Q65345518-63A322F6-8C2E-44A1-A5C5-97FD442CD98C @default.
- Q65345518 P17 Q65345518-86570921-E37E-475C-952A-F970818F84B9 @default.
- Q65345518 P17 Q65345518-D6C9943C-0206-4621-8070-81DA0CF065EF @default.
- Q65345518 P1813 Q65345518-BE3B3FF0-EAD3-4DDA-9434-BD94B9B4E9D8 @default.
- Q65345518 P2899 Q65345518-FA1804C1-893A-4743-A141-66F06A6C5704 @default.
- Q65345518 P3098 Q65345518-00DDBE23-2C70-45EA-A833-BAE4E37292E7 @default.
- Q65345518 P31 Q65345518-2BA3328D-A100-4FC3-806D-9CF0DD86A3D1 @default.
- Q65345518 P580 Q65345518-1A89A2E0-FDD3-46E7-921E-A193F3A2A2E1 @default.
- Q65345518 P582 Q65345518-02B534F9-CF09-4CEC-B21B-F25D0FECE50C @default.
- Q65345518 P6099 Q65345518-FF69019F-CC13-4C5F-B387-9F288B773F11 @default.
- Q65345518 P8363 Q65345518-81ACB743-FDFD-438C-9FA0-18E1215E72BB @default.
- Q65345518 P1132 "+486" @default.
- Q65345518 P1476 "A Randomized, Multicenter, Open-label, Phase II Trial to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With HER2 Negative, ER+ Metastatic Breast Cancer" @default.
- Q65345518 P17 Q142 @default.
- Q65345518 P17 Q145 @default.
- Q65345518 P17 Q183 @default.
- Q65345518 P17 Q29 @default.
- Q65345518 P17 Q38 @default.
- Q65345518 P1813 "PARSIFAL" @default.
- Q65345518 P2899 "+18" @default.
- Q65345518 P3098 "NCT02491983" @default.
- Q65345518 P31 Q30612 @default.
- Q65345518 P580 "2015-08-01T00:00:00Z" @default.
- Q65345518 P582 "2019-12-01T00:00:00Z" @default.
- Q65345518 P6099 Q42824440 @default.
- Q65345518 P8363 Q78089383 @default.